Hossein Pakdaman, M.D
Professor of Neurology Beheshti University School of Medicine since 1990.

Professional Society Memberships:
Director of Medical Education in Loghman Adham Medical Center (1979-1982)
Associate of the Education Deputy of Beheshti University School of Medicine (1980-1982)
Head of Neurology Service in Loghman Adham Medical Center (since 1978)
Chairman of Neurology Department Beheshti University School of Medicine (since 1978)
Director of Iranian Neurological Board Examination (since 1978)
President of Iranian Neurological Congress (since 1974)
President of 16 International Iranian Neurological Association (since 1991)
Chairman of Iranian Neurological Journal (since 1998).

Journal Article (English)

1) Alipour M, Nabavi SM, Arab L, Vosough M, Pakdaman H, Ehsani E, Shahpasand K. Stem cell therapy in Alzheimer#39;s disease: possible benefits and limiting drawbacks. Mol Biol Rep. 2018 Dec 18. doi: 10.1007/s11033-018-4499-7.

2) Pakdaman H, Abbasi M, Gharagozli K, Ashrafi F, Delavar Kasmaei H, Amini Harandi A. A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis. Neurol Sci. 2018 Dec;39(12):2107-2113.

3) Pakdaman H, Amini Harandi A, Gharagozli K, Abbasi M, Ghaffarpour M, Ashrafi F, Delavar Kasmaei H, Amini Harandi A. MLC601 in vascular dementia: an efficacy and safety pilot study. Neuropsychiatr Dis Treat. 2017 Oct 5;13:2551-2557.

4) Amini Harandi A, Esfandani A, Pakdaman H, Abbasi M, Sahraian MA. Balo#39;s concentric sclerosis: an update and comprehensive literature review. Rev Neurosci. 2018 Nov 27;29(8):873-882.

5) Pakdaman H, Gharagozli K, Abbasi M, Sobhanian A, Bakhshandehpour A, Ashrafi F, Khalilzad M, Amini Harandi A. Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study. Dement Geriatr Cogn Dis Extra. 2018 Apr 26;8(1):174-179.

6) Rezaei O, Pakdaman H, Gharehgozli K, Simani L, Vahedian-Azimi A, Asaadi S, Sahraei Z, Hajiesmaeili M. S100 B: A new concept in neurocritical care. Iran J Neurol. 2017 Apr 4;16(2):83-89.

7) Pakdaman H, Amini Harandi A, Abbasi M, Delavar Kasmaei H, Ashrafi F, Gharagozli K, Assarzadegan F, Behnam B, Arabahmadi M. Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study. Dement Geriatr Cogn Dis Extra. 2017 May 4;7(1):136-142.

8) Ashrafi F, Pakdaman H, Arabahmadi M, Behnam B. Head Trauma as a Precipitating Factor for Late-onset Leigh Syndrome: a Case Report. Emerg (Tehran). 2017;5(1):e43.

9) Pakdaman H, Amini Harandi A, Abbasi M, Karimi M, Arami MA, Mosavi SA, Haddadian K, Rezaei O, Sadeghi S, Sharifi G, Gharagozli K, Bahrami P, Ashrafi F, Kasmae HD, Ghassemi A, Arabahmadi M, Behnam B. Vagus nerve stimulation in drug-resistant epilepsy: the efficacy and adverse effects in a 5-year follow-up study in Iran. Neurol Sci. Sci. 2016 Nov;37(11):1773-1778.

10) Asaadi S, Ashrafi F, Omidbeigi M, Nasiri Z, Pakdaman H, Amini-Harandi A. Persian version of frontal assessment battery: Correlations with formal measures of executive functioning and providing normative data for Persian population. Iran J Neurol. 2016 Jan 5;15(1):16-22.

11) Ashrafi F, Behnam B, Arab Ahmadi M, Sanei Taheri M, Haghighatkhah HR, Pakdaman H, Kharrazi SM. Correlation of MRI findings and cognitive function in multiple sclerosis patients using montreal cognitive assessment test. Med J Islam Repub Iran. 2016 Apr 17;30:357.

12) Pakdaman H, Amini Harandi A, Gharagozli K, Abbasi M, Tabassi A, Ashrafi F, Ghaffarpor M, Sharifi S, Delavar Kasmae H, Assarzadegan F, Arabahmadi M, Behnam B. Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran. Int J Neurosci. 2016 Jul 19:1-7.

13) Pakdaman H, Harandi AA, Hatamian H, Tabatabae M, Delavar Kasmaei H, Ghassemi A, Gharagozli K, Ashrafi F, Emami Naeini P, Tavakolian M, Shahin D. Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer#39;s Disease: A Multicenter, Randomized Controlled Trial. Dement Geriatr Cogn Dis Extra. 2015 Mar 7;5(1):96-106.

14) Ashrafi Farzad, Sina Asaadi, Hosein Pakdaman, Alireza Zali, Ali Amini Harandi. Repetitive Transcranial Magnetic Stimulation on Motor Functions recovery in Subcortical Stroke. Caspian.J.Neurol. Sci 2015, 1(1): 1-6

15) Frontal assessment battery in a Persian population with Parkinson#39;s disease. ICNSJ 2014; 1 (1):18-21.

16) Cognitive impairments in Parkinson#39;s disease: Evidence from an Iranian population. Iranian Journal of Neurology 2012. 11(4):151-4.

17) Association Between Cognitive Function and Metabolic Syndrome Using Montreal Cognitive Assessment Test. ICNSJ 2015; 2 (3) :91-96.

18) Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer#39;s disease: A Multicenter, Randomized Controlled Trial. Dement Geriatr Cogn Dis Extra. 2015 Mar 7;5(1):96-106.

19) Vitamin D and multiple sclerosis. Iran J Neurol. 2014;13(1):1-6.

20) Trigeminal neuralgia as the first clinical manifestation of anti-hu paraneoplastic syndrome induced by a borderline ovarian mucinous tumor. Case Rep Neurol. 2014 Jan 22;6(1):7-13.

21) Pharmacokinetic and pharmacodynamic properties of the new AEDs: A review article. Iran J Neurol. 2013;12(4):157-65.

22) Characteristics of multiple sclerosis in the Middle East with special reference to the applicability of international guidelines to the region. Int J Neurosci. 2014 Sep;124(9):635-41.

23) Efficacy and Tolerability of MlC601 in Patients with Mild to Moderate Alzheimer Disease who were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine. British Journal of Medicine Medical Research. 2013; 3(2): 341-350.

24) Vitamin D3 concentration correlates with the severity of multiple sclerosis. Int J Prev Med. 2013 May;4(5):585-91.

25) Epidemiology of headaches in Tehran urban area: a population-based cross-sectional study in district 8, year 2010. Neurol Sci. 2012 Sep 26.

26) Frequency distribution of the first clinical symptoms in the Iranian population with multiple sclerosis. Iranian J Neurology. 2012; 11(3): 118-120.

27) Is it time to revise the classification of geographical distribution of MS? Ir J Neurol. 2012: 11(2).
28) Barking seizure: acute episodes of barking in a 75-year-old previously healthy man. Seizure. 2012 May;21(4):304-6.

29) Serum prolactin level in patients with relapsing-remitting multiple sclerosis during relapse. J Clin Neurosci. 2012 Apr;19(4):622-3.

30) Old findings in multiple sclerosis but a new application. Clin Neurol Neurosurg. 2012 May;114(4):411.

31) The effect of NeuroAiDtrade; (MLC601) on cerebral blood flow velocity in subjects#39; post brain infarct in the middle cerebral artery territory. Eur J Intern Med. 2011 Oct;22(5):509-13.

32) Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial. Stroke Res Treat. 2011;2011:721613.

33) Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time. Eur Neurol. 2010;64(6):331-6.

34) Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. Toxicol Mech Methods. 2010 Oct;20(8):452-7.

35) Biosimilars: opinion of an expert panel in the Middle East. Curr Med Res Opin. 2008 Oct;24(10):2897-903.

36) International Working Group for Treatment Optimization in MS. Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Curr Med Res Opin. 2007 Nov;23(11):2823-32.

37) Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurol Scand. 2007 Jun;115(6):429-31.

38) Pakdaman H, Fallah A, Sahraian MA, Pakdaman R, Rahimian E. Early-onset multiple sclerosis: a report of a monozygotic twin pair with different treatment strategies and outcomes. Eur J Neurol. 2007 Feb;14(2):e10.

39) Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. europediatrics.2006 Aug;37(4):257-60.

40) SIGN Group. Quality of life of people with epilepsy in Iran, the Gulf, and Near East. Epilepsia. 2005 Jan;46(1):132-40.

41) A six-month cross-section study on prevalence and characteristics of pain in 100 Iranian patients with Multiple Sclerosis, Multiple Sclerosis Journal, Volume 10, Supplement 2, September 2004, p229.

42) Childhood onset of inflammatory demyelinating diseases of the central nervous system: a retrospective review. Multiple Sclerosis Journal, Volume 10, Supplement 2, September 2004, p342.

43) Assessing the treatment of relapsing-remitting multiple sclerosis beta -1a in 2 groups of Iranian patients (120) with mild to moderate disability after one year, Multiple Sclerosis Journal, Volume 10, Supplement 2, September 2004, p573.

44) Direct comparison study of the effect of beta-interferons in Iranian patients with Multiple Sclerosis. (Results of a 6-year therapy), Journal of Neurology (ENS), Volume 251, suppl.3, June 2004, p230.

45) Lamictal as an add on therapy in the treatment of 100 Iranian patients with Trigeminal Neuralgia, Journal of Neurology (ENS), Volume 251, suppl.3,June 2004, p550.

46) The epidemiology of Multiple Sclerosis in Iran, Journal of Neurology (ENS), Volume 250, suppl.2, May 2003, p774.

47) Comparison Effectiveness and safety of Sodium Valproate, Carbamazepine and Topamax in 180 Iranian with psychomotor epilepsy, 1st Sharm el Sheikh International Epilepsy conference, March 5-8, 2003, p42.

48) Assessment of signs and symptoms in Multiple Sclerosis and evaluation of disability condition in patients referred to MS research clinics from1997-2001 (2412 cases), Multiple Sclerosis Journal, Volume8, Supplement 1, September 2002, p41.

49) The effect of Interferon Beta on the cognitive dysfunction of 100 Iranian patients with Multiple Sclerosis, Multiple Sclerosis Journal, Volume8, Supplement 1, September 2002, p288.

50) The changes in the transmission functioning of the ulnar nerve in a high power magnetic field. Electromyogr Clin Neurophysiol. 2001 Jul-Aug;41(5):269-71.

51) Comparison of the efficacy and tolerability of treatment Carbamazepin and Sodium Valproate monotherapy for newly diagnosed complex partial seizure. Iranian Journal of Neurology, Volume 1, Number 4, winter 2001.

52) Effectiveness, tolerability and safety of Topiramate in treatment of children with resistant epilepsy. - Iranian Journal of Neurology, Volume 2, Summer 2001

53) Double blind placebo controlled randomized parallel group trials study compared the efficacy, safety and tolerability of oral Sumatriptan on 40 Iranian patients with acute migraine headaches. ndash; Iranian Journal of Neurology, Volume 1, Number 1,May 2001.

54) Comparison of the efficacy and tolerability of Avonex, Rebif and betaferon on 100 Iranian MS patients (5 years study) cognitive dysfunction in multiple sclerosis. - Iranian Journal of Neurology, Volume 1, Number 1,May 2001

55) Assessment of sign and symptom in Iranian Multiple Sclerosis Patient: Iranian Neurological Journal Volume 2, 2001).

56) The effect of interferon beta on cognitive dysfunction of 100 Iranian patients with multiple sclerosis- MS Journal, Volume2, 1999.

57) Open label clinical study on effectiveness of Topiramate as add -on therapy on 22 patients with partial onset of seizure with or without generalization; Epilepsia (volum16, 1999)

58) Efficacy and Safety of Lamotrigine as add-on Therapy on 13,132 children and adult Iranian patient with treatment resistant Epilepsy: Epilepsia (volume 14,1999).

59) Vagus Nerve Stimulation: Epilepsia (volume 1999).

Books:
Golden keys in neurology
Essentials of diagnosis and treatment in toxicology
Chemical and pharmalogical toxicology
Practical neuroanatomy
Illustrated Case Reports in Neurology (The Year book of the 2015 Aboreiyhan Festival)
Clinical Neurology
Epilepsy
Intercranical Doppler Sonography